ALNYLAM PHARMACEUTICALS INC (ALNY)

Jefferies Taps Former Alnylam CEO Maraganore as Senior Adviser

Investment bank Jefferies Financial Group Inc. has hired former Alnylam Pharmaceuticals Inc. Chief Executive Officer John Maraganore as a senior adviser.

Alnylam Pharmaceuticals Larger Than S&P 500 Component United Airlines Holdings

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Pharmaceuticals Enters Oversold Territory (ALNY)

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam to Webcast TTR Investor Day

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Noteworthy Friday Option Activity: ALNY, AMRK, DKNG

Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations

The company is hoping to rival Pfizer's approved treatment for cardiomyopathy.

Alnylam Falls as Heart Disease Drug Data Disappoint Investors

Alnylam Pharmaceuticals Inc. plummeted after full results from a trial its drug to treat a progressive and deadly form of heart disease disappointed investors.

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

The 3 Best Gene Editing Stocks to Buy in August 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.